GNRSU stock falls to $0.000001 on PNK 23 Jan 2026: what investors should watch
GNRSU stock plunged to $0.000001 on the PNK exchange on 23 Jan 2026 during market hours, marking it one of the top losers today with a -99.99933% one‑day move. The Greenrose Holding Company Inc. (GNRSU) now trades at a market cap of USD 13.00 and volume of 145 shares, after a previous close of USD 0.15. We break down why the collapse happened, what the company metrics show, and the key signals traders should monitor going forward.
Price action and top losers context
GNRSU stock moved to $0.000001 on PNK in regular market hours on 23 Jan 2026, a drop of -99.99933% from the prior close. This puts GNRSU among the day’s top losers in the healthcare/drug manufacturers sector and the sharp decline explains the abnormally low trading price and tiny daily range.
Volume was light at 145 shares, suggesting the move was driven by a specific sell event or corporate action rather than broad market selling. Traders should note the year high of $0.151 and year low of $0.000001 for context on the recent volatility.
Company profile and fundamentals
The Greenrose Holding Company Inc. (GNRSU) is listed on PNK in the United States and operates in the healthcare sector, industry: Drug Manufacturers – Specialty & Generic. The company reports 91 full‑time employees and is headquartered in Amityville, NY.
Trailing metrics show EPS 3.10 and a PE ratio effectively near zero because the share price collapsed to micro levels. Book value per share is 4.30, cash per share is 0.56, and shares outstanding are 12,853,627. These mixed signals mean accounting profits exist but the market has priced the equity at near‑zero levels.
Balance sheet signals and valuation ratios
Key ratios point to stressed liquidity: current ratio 0.21 and cash ratio 0.06, while debt to equity is 1.57, indicating leverage risk relative to equity. The enterprise value figures from our data imply extreme distortion given the tiny market cap of USD 13.00 and enterprise value listed at USD 101,417,768.00, which signals data or float anomalies worth reconciling with filings.
Price multiples are artificially compressed: price to book and price to sales ratios round to near zero because the listed market price is miniscule. That disparity increases risk for investors relying solely on headline multiples.
Technical picture and trading setup
GNRSU’s short technical history shows an abrupt collapse from its 50‑day and 200‑day averages at $0.15, leaving no meaningful intraday range today (day low and day high both $0.000001). With average volume data missing and only 145 shares traded today, liquidity is extremely thin and bid/ask spreads are likely wide.
For traders, this is a high‑volatility, low‑liquidity setup. Stop placement and position sizing must account for execution risk and potential listing or corporate developments that can change price behavior rapidly.
Meyka grade and analyst context
Meyka AI rates GNRSU with a score out of 100: Score: 63.03 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
This grade is informational and not investment advice. The B grade reflects positive historical margins and reported EPS, offset by market pricing anomalies, thin liquidity, and balance sheet pressure. Investors should reconcile company filings and recent corporate actions before acting.
Catalysts, risks, and sector context
Catalysts that could change GNRSU stock include corporate announcements, reverse splits, capital raises, or regulatory updates in the cannabis and specialty drug space. Greenrose sits in the healthcare/cannabis niche, where sector flows and state policy shifts matter.
Major risks include continued illiquidity, possible delisting on major venues, shareholder dilution from financings, and operational execution in cultivation and processing. Given the sector’s trading patterns, broader healthcare or cannabis rallies may not lift GNRSU until structural liquidity returns.
Final Thoughts
Key takeaways: GNRSU stock traded at $0.000001 on the PNK exchange on 23 Jan 2026, a one‑day drop of -99.99933% that places it among today’s top losers. The Greenrose Holding Company Inc. shows positive trailing accounting metrics such as EPS 3.10 and book value per share 4.30, but market pricing, thin volume (145 shares), and weak liquidity create execution and valuation risks. Meyka AI’s forecast model projects a scenario recovery to $0.05 within 12 months from current quote, implying an upside of approximately 4,999,900.00% vs the current listed price; forecasts are model‑based projections and not guarantees. Our Meyka grade remains B (63.03) with a HOLD suggestion while we await clearer corporate filings or liquidity events. Investors should treat GNRSU as speculative, verify filings at the company site, and consider position sizing limits given the fragile trading profile.
FAQs
Why did GNRSU stock drop to near zero on 23 Jan 2026?
The fall to $0.000001 on PNK reflects an acute price collapse likely tied to a sell event or corporate action combined with very low liquidity. Confirm details in company filings and market notices before trading.
What does Meyka AI say about GNRSU stock performance?
Meyka AI rates GNRSU with a 63.03 score (Grade B, HOLD). The grade balances reported profitability against extreme market pricing and liquidity risk; it is informational, not individualized advice.
Is there a realistic GNRSU stock forecast or price target?
Meyka AI’s forecast model projects a recovery scenario to $0.05 within 12 months, but this is model‑based and not guaranteed. Given current price and low volume, any target carries high execution risk.
What should traders watch next for GNRSU stock?
Watch official company releases, SEC or OTC notices, sudden volume spikes, and any reverse split or financing announcements. Those events can materially change GNRSU stock liquidity and quoted price.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
